Differentiating Pancreatic Diseases
with Precision Diagnostics
At PRELIQX, we are expanding the boundaries of innovation in molecular diagnostics with our groundbreaking liquid biopsy-based test for pancreatic diseases. Pancronin® is designed to differentiate between various types of pancreatic diseases with unparalleled accuracy.
Why Accurate Differentiation Matters?
Approximately 35 million individuals around the world are currently affected by various symptomatic pancreatic diseases. They often present with overlapping symptoms, making precise diagnosis challenging. Accurate differentiation is crucial to guide the selection of targeted therapies, minimize risks, and optimize patient outcomes. Misdiagnosis or delayed differentiation can lead to inappropriate treatments, exposing patients to unnecessary side effects or delaying the initiation of life-saving interventions.
Our Solution
Pancronin® harnesses advanced liquid biopsy technology to analyze disease-specific biomarkers from a simple blood sample. It provides a minimally invasive, fast, and reliable diagnostic option, streamlining the diagnostic process for both clinicians and patients.
Molecular Profiling for Pancreatic Disease Differentiation
Pancronin® composed of a comprehensive panel of molecular markers has been developed to facilitate accurate discrimination between pancreatic diseases through the innovative use of liquid biopsy techniques.
Key Features and Benefits:
Non-invasive: Requires only a small blood sample.
Accurate Differentiation: Identifies disease-specific biomarkers for precise diagnosis.
Time-Saving: Accelerates diagnosis and reduces the time to treatment.
Broad Clinical Applications: Supports diagnostic needs across oncology, gastroenterology, and internal medicine.
Empowering Drug Development: Acts as a surrogate marker in clinical trials, aiding pharmaceutical innovation.
Partner with Us
PRELIQX invites clinicians, researchers, healthcare providers, and industry stakeholders to join us in revolutionizing pancreatic disease diagnostics. Together, we can pave the way for a healthier future. Reach out to learn more or collaborate.
References
Pancreatic Cancer: Statistics | Cancer.Net
Lancet Gastroenterol Hepatol. 2016 Sep;1(1):45-55.
BMC Gastroenterol. 2021 Aug 25;21(1):332.
Hartwig C et al. Mol Cancer. 2024 Feb 2;23(1):28.
Wu Y, et al. Gut. 2023 Nov 24;72(12):2344-2353.
Manoochehri M et al. Mol Oncol. 2020;14:1252–67.
